AEGERION PHARMACEUTICALS COMPLETES $22.5 MILLION VENTURE CAPITAL
Aegerion Pharmaceuticals, Inc., a specialty pharmaceuticals company formed to focus on the development of compounds to treat cardiovascular and metabolic disease, today announced the closing of its $22.5 million Series A financing. Led by Advent International, the financing included participation by Index Ventures, Alta Partners, and MVM Life Science Partners. The capital is supporting further development of its lead compounds that have
been shown to significantly reduce LDL cholesterol.
American Venture Magazine